| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/23/2006 | US20060063747 Paroxetine cholate or cholic acid derivative salts, and composition comprising paroxetine and cholic acid or derivative thereof |
| 03/23/2006 | US20060063746 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators |
| 03/23/2006 | US20060063745 Composition for relieving pain and improving mobility |
| 03/23/2006 | US20060063744 Method of treating patients undergoing kidney dialysis |
| 03/23/2006 | US20060063743 Peptide deformylase activated prodrugs |
| 03/23/2006 | US20060063742 Method of treatment for or protection against lymphedema |
| 03/23/2006 | US20060063740 Method for inhibiting bone resorption |
| 03/23/2006 | US20060063739 2-Substituted heteroaryl compounds |
| 03/23/2006 | US20060063738 Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof |
| 03/23/2006 | US20060063737 Liquid paroxetine compositions |
| 03/23/2006 | US20060063736 Compositions and methods for inhibiting mucin-type O-linked glycosylation |
| 03/23/2006 | US20060063735 Salts of 5-azacytidine |
| 03/23/2006 | US20060063731 In vivo inhibition of hepatitis B virus |
| 03/23/2006 | US20060063728 Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease |
| 03/23/2006 | US20060063727 Tr4/tr2 response elements |
| 03/23/2006 | US20060063726 Crystallization in ethanol, propanol, or isopropanol solvent; acidification, evaporation; anticarcinogenic agents |
| 03/23/2006 | US20060063725 Process of preparing a crystalline azithromycin monohydrate |
| 03/23/2006 | US20060063723 Pharmaceutical composition comprising esterol derivatives for use in cancer therapy |
| 03/23/2006 | US20060063722 Compound similar to dapaglifozin, but with ethyl group replacing the ethoxy group |
| 03/23/2006 | US20060063721 AI-2 compounds and analogs based on salmonella typhimurium LsrB structure |
| 03/23/2006 | US20060063720 Oxaliplatin solution concentrate |
| 03/23/2006 | US20060063719 Methods for treating diabetes |
| 03/23/2006 | US20060063718 Topical glutathione compositions |
| 03/23/2006 | US20060063712 Pharmaceutical composition for inhibiting influenza virus infection and reproduction |
| 03/23/2006 | US20060063711 Use of sglt homolog |
| 03/23/2006 | US20060063707 Compositions for enhancing memory and methods therefor |
| 03/23/2006 | US20060063703 Methods for treating cancer-related fatigue |
| 03/23/2006 | US20060063702 Neuromedin U 2 receptor agonists and uses thereof |
| 03/23/2006 | US20060063299 Scaffold-organized clusters and electronic devices made using such clusters |
| 03/23/2006 | US20060063258 Retinoic acid receptor beta-2, its agonists, and gene therapy vectors for the treatment of neurological disorders |
| 03/23/2006 | US20060063235 DNA encoding the human serine protease C-E |
| 03/23/2006 | US20060063226 Method for the biotransformation of carotenoids by means of a cytochrome p450 monooxygnase |
| 03/23/2006 | US20060063213 Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
| 03/23/2006 | US20060063212 Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
| 03/23/2006 | US20060062864 Containing vitex agnus castus (Chastetree berry) extract; impulsive eating and/or bingeing prevention; modulating dopamine receptors |
| 03/23/2006 | US20060062862 Cholesterol-reducing agent made of dietary fibre and cholesterol-reducing substances |
| 03/23/2006 | US20060062860 Use of anemonin for treating aseptic inflammations |
| 03/23/2006 | US20060062859 Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes |
| 03/23/2006 | US20060062856 Controlled release galantamine composition |
| 03/23/2006 | US20060062853 Treating neuromuscular disorders with an oral formulation of creatine derivatives |
| 03/23/2006 | US20060062849 Oral formulation of creatine derivatives and method of manufacturing same |
| 03/23/2006 | US20060062848 Formulation comprising itraconazole |
| 03/23/2006 | US20060062846 Alfuzosin tablets and synthesis |
| 03/23/2006 | US20060062842 Method of administering a compound to multi-drug resistant cells |
| 03/23/2006 | US20060062829 Medical pad, and method for making and using |
| 03/23/2006 | US20060062828 feeding animals such as cats and rabbits prone to hairball formation, with proteins, fats, dietary fibers and blends of beet pulp and carboxymethyl cellulose and salts |
| 03/23/2006 | US20060062823 Microtubule stabilisers for treating stenosis in stents |
| 03/23/2006 | US20060062822 Medical devices to treat or inhibit restenosis |
| 03/23/2006 | US20060062812 Novel compositions |
| 03/23/2006 | US20060062810 Microemulsion concentrate for oral administration of water-insoluble anti-cold drug and method for preparing same |
| 03/23/2006 | US20060062809 Solid dispersions comprising two different polymer matrixes |
| 03/23/2006 | US20060062803 a nucleic acid fhaving a first nucleotide sequence encoding nonstructural proteins from attenuated dengue-2 virus vaccine strain PDK-53, and a second nucleotide sequence encoding a structural protein from a second flavivirus; amino acid mutations in the nontstructural proteins; vaccines |
| 03/23/2006 | US20060062800 Immunogens; envelope proteins; kits |
| 03/23/2006 | US20060062791 I kappa B kinase complex as a target for the treatment of Huntington's disease |
| 03/23/2006 | US20060062788 Method for determining MIF content |
| 03/23/2006 | US20060062787 Method for treating Sjogren's syndrome |
| 03/23/2006 | US20060062769 Using nestin-positive pancreatic stem cell to generate insulin producing beta cells; tissue engineering and repair; regenerative medicine |
| 03/23/2006 | US20060062762 Method of cancer treatment; method of diabetes treatment; method of multiple sclerosis treatment; method of interstitial cystitis treatment; method of acquired immune deficiency syndrome treatment; and method of herpes treatment |
| 03/23/2006 | US20060062759 Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
| 03/23/2006 | US20060062757 mixing imiquimod and a base cream, then topically administering the resulting mixture, in conjunction with vaccines containing tumor necrosis factors, and valacyclovir tablets admistered by mouth, and testing for tumor markers; mammary glands |
| 03/23/2006 | US20060062756 Method of cancer screening; method of cancer treatment; method of diabetes treatment; method of multiple sclerosis treatment; method of interstitial cystitis treatment; method of acquired immune deficiency syndrome treatment; and method of herpes treatment |
| 03/23/2006 | US20060062755 medical diagnosis using tumor markers; concurrent transdermal administration of imiquimod and injection of vaccines containing tumor necrosis factors; anticarcinogenic agents |
| 03/23/2006 | US20060062753 Polymeric quaternary ammonium salts useful as corrosion inhibitors and biocides |
| 03/23/2006 | US20060062750 applying mixtures of diclofenac or salts, benzyl alcohol, polyethylene glycol monomethyl ether, sodium hyaluronate and water, for the treatment of skin disorders: dermatology |
| 03/23/2006 | US20060062747 Use of sweetener acids for the microbiological stabilization of foodstuffs, cosmetic products, consumer goods and pharmaceutical productions |
| 03/23/2006 | US20060062745 Lupeol anti-tumor agent and uses thereof |
| 03/23/2006 | US20060062729 Enhanced ligand binding to neurotensin receptors |
| 03/23/2006 | US20060060406 Mounting configuration and method for a motorcycle seat |
| 03/23/2006 | DE19826517B4 Verfahren zur Herstellung von Filmtabletten mit Cyclophosphamid als Wirkstoff und daraus hergestellte Cyclophosphamid-Filmtablette Process for the preparation of film-coated tablets with cyclophosphamide as active ingredient and cyclophosphamide film-coated tablet prepared therefrom |
| 03/23/2006 | DE19723155B4 Verwendung eines Eisensalzes der Alginsäure zur Therapie rheumatischer Erkrankungen Use of an iron salt of alginic acid for the treatment of rheumatic diseases |
| 03/23/2006 | DE10318714B4 Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches Drug combinations and therapies to combat alcohol abuse |
| 03/23/2006 | DE102004046012A1 New D-glucopyranosylphenyl-substituted cyclic compounds useful as sodium-dependent glucose cotransporter inhibitors for treating metabolic diseases, e.g. diabetes |
| 03/23/2006 | DE102004045825A1 Lyophilisat enthaltend N-Diaminomethylen-2-methyl-4,5-di-(methylsulfonyl)-benzamid Lyophilisate containing N-diaminomethylene-2-methyl-4,5-di (methylsulfonyl) benzamide |
| 03/23/2006 | DE102004045796A1 Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung Medicines containing carbonyl compounds and their use |
| 03/23/2006 | DE102004045720A1 Stabile Dosierungsform von Phenylalanin-Derivaten Stable dosage form of phenylalanine derivatives |
| 03/23/2006 | DE102004045648A1 Neue Betamimetika zur Behandlung von Atemwegserkrankungen New beta-mimetics for the treatment of respiratory disorders |
| 03/23/2006 | DE102004039509A1 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Aryl-cycloalkyl substituted alkane acid derivatives, processes for their preparation and their use as medicaments |
| 03/23/2006 | DE102004036641A1 Verzögert freisetzende pharmazeutische Zusammensetzung, die Venlafaxin enthält The sustained release pharmaceutical composition containing venlafaxine |
| 03/23/2006 | DE102004036314A1 New D-glucopyranosylphenyl-substituted cyclic compounds useful as sodium-dependent glucose cotransporter inhibitors for treating metabolic diseases, e.g. diabetes |
| 03/23/2006 | DE10037121B4 Verwendung einer konzentrierten und stabilisierten antipyretischen Zusammensetzung für den tiermedizinischen Gebrauch als Zusatz zu Tiernahrung Using a concentrated and stabilized antipyretic composition for veterinary use as an additive to animal feed |
| 03/23/2006 | CA2764314A1 Process for production of optically active amine derivatives |
| 03/23/2006 | CA2620208A1 Methods and compositions for the treatment of hyperlipidemia |
| 03/23/2006 | CA2607177A1 Betulinol derivatives as anti-cancer agents |
| 03/23/2006 | CA2601996A1 Purine derivatives as a3 and a1 adenosine receptor agonists |
| 03/23/2006 | CA2584714A1 Covered stent with controlled therapeutic agent diffusion |
| 03/23/2006 | CA2584528A1 Composition for inhibiting or preventing the formation of a biofilm |
| 03/23/2006 | CA2583410A1 Thyroid hormone analogs for promoting angiogenesis |
| 03/23/2006 | CA2581144A1 Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors |
| 03/23/2006 | CA2581076A1 D-methionine formulation with improved biopharmaceutical properties |
| 03/23/2006 | CA2580979A1 Novel compounds useful for modulating abnormal cell proliferation |
| 03/23/2006 | CA2580805A1 Use of tellurium compounds as adjuvants |
| 03/23/2006 | CA2580804A1 Compositions and methods for inducing hair growth |
| 03/23/2006 | CA2580692A1 Use of glutamic acid or salts thereof in preventing or improving functional digestive disorder |
| 03/23/2006 | CA2580659A1 Corticosteroid having low systemic absorption |
| 03/23/2006 | CA2580656A1 Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors |
| 03/23/2006 | CA2580643A1 Use of tellurium compounds for inhibition of interleukin-converting enzyme |
| 03/23/2006 | CA2580642A1 Novel tellurium compounds and their use as immunomodulators |
| 03/23/2006 | CA2580627A1 Nitrate esters and their use for mitigating cellular damage |
| 03/23/2006 | CA2580601A1 Novel compounds useful for modulating abnormal cell proliferation |
| 03/23/2006 | CA2580564A1 Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds |